Praluent 75 mg/mL

Alirocumab, the active ingredient in Praluent 75 mg/mL, is a PCSK9 inhibitor presented as a 75 mg/mL injection, solution for subcutaneous use. It is used to lower LDL cholesterol in adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or atherosclerotic cardiovascular disease (ASCVD) as an adjunct to diet and maximally tolerated statin therapy.

GNH USA supplies Praluent 75 mg/mL as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

Praluent 75 mg/mL is a PCSK9 inhibitor used to manage cholesterol levels and support cardiovascular health. It is indicated for the following conditions:

- Heterozygous Familial Hypercholesterolemia (HeFH): Reduces LDL cholesterol levels in patients with this genetic condition. - Homozygous Familial Hypercholesterolemia (HoFH): Helps lower LDL cholesterol in patients with this severe genetic disorder. - Atherosclerotic Cardiovascular Disease (ASCVD): Used as an adjunct to diet and maximally tolerated statin therapy to reduce the risk of cardiovascular events in patients with established ASCVD.

Praluent 75 mg/mL may cause side effects, although not everyone gets them. Common Side Effects: - Injection site reactions, such as redness, swelling, or itching. - Nasopharyngitis (common cold symptoms). - Upper respiratory tract infection. - Flu-like symptoms. - Back pain. - Diarrhea.

Serious or Rare Side Effects: - Hypersensitivity reactions, including rash, hives, and difficulty breathing. - Allergic reactions, which may require immediate medical attention. - Neurological symptoms, such as memory problems or confusion. - Increased risk of diabetes, as seen with some cholesterol-lowering medications.

Praluent 75 mg/mL should be used with caution and under medical supervision. Important precautions include: - Allergic Reactions: Inform your doctor if you have a history of allergic reactions to alirocumab or any of its components. - Liver Function: Regular monitoring of liver function is recommended during treatment. - Pregnancy and Breastfeeding: The safety of Praluent during pregnancy and breastfeeding has not been established; consult your doctor. - Use in Children: Safety and efficacy in children have not been fully established. - Storage: Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Praluent 75 mg/mL may interact with other medications, potentially affecting its efficacy or increasing the risk of side effects. Major Interactions (Avoid): - None identified.

Moderate Interactions (Monitor Closely): - Statin Therapy: Statin co-administration may increase the production of PCSK9, potentially affecting the efficacy of Praluent. - Ezetimibe: May require monitoring for changes in LDL cholesterol levels. - Other Lipid-Lowering Therapies: May need dose adjustments or monitoring when used in combination with Praluent.